Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: A randomized, double-blind, placebo-controlled study
(Source: Journal of Critical Care)
Source: Journal of Critical Care - June 19, 2014 Category: Gastroenterology Authors: Florian Beigel, Niels Teich, Stefanie Howaldt, Frank Lammert, Jochen Maul, Simone Breiteneicher, Christian Rust, Burkhard Göke, Stephan Brand, Thomas Ochsenkühn Source Type: research
Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review
(Source: Diabetic Medicine)
Source: Diabetic Medicine - June 18, 2014 Category: Endocrinology Authors: R. S. Elkeles Tags: Letters Source Type: research
Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin
Conclusions: Aspirin, atenolol, enalapril, rosiglitazone, and sitagliptin may be taken with colesevelam. Although the phenytoin study indicated no pharmacokinetic interaction, phenytoin should continue to be taken ≥4h before colesevelam in accordance with current prescribing information. (Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - April 10, 2014 Category: Endocrinology Authors: Ling He, Prachi Wickremasingha, James Lee, Ben Tao, Jeanne Mendell-Harary, Joseph Walker, Douglas Wight Tags: Basic Research Source Type: research
Systematic review: the management of chronic diarrhoea due to bile acid malabsorption
ConclusionsColestyramine and colestipol are generally effective treatments of gastrointestinal symptoms from BAM, but may be poorly tolerated and reduce the bioavailability of co‐administered agents. Alternative therapies (including colesevelam and aluminium hydroxide) as well as dietary intervention may also have a role, and the promising results of the first proof‐of‐concept study of obeticholic acid suggest that its novel approach may have an exciting future in the treatment of this condition. Future trials should employ accurate diagnostic testing and be conducted over longer periods so that the long‐term benef...
Source: Alimentary Pharmacology and Therapeutics - March 7, 2014 Category: Drugs & Pharmacology Authors: C. Wilcox, J. Turner, J. Green Tags: Systematic Review Source Type: research
Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review
This article is protected by copyright. All rights reserved. (Source: Diabetic Medicine)
Source: Diabetic Medicine - March 1, 2014 Category: Endocrinology Authors: R. S. Elkeles Tags: Letter Source Type: research
Repurposed Drugs in Metabolic Disorders.
Abstract
Drug repurposing (drug repositioning, drug reprofiling, drug retasking) gains increasing importance as the development of new drugs becomes increasingly expensive. Though only a few compounds have been approved for new indications in the field of metabolic disorders, there are a number of substances which have the potential to become reprofiled in a new indication. Generally, reprofiled drugs for metabolic disorders can be classified in three groups. Group A contains those of which both, the original and repurposed indication, concern metabolic disorders. Group B comprises drugs, which were origin...
Source: Current Topics in Medicinal Chemistry - September 20, 2013 Category: Chemistry Authors: Finsterer J, Frank M Tags: Curr Top Med Chem Source Type: research
Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review*
ConclusionThe limited number of studies concerning the treatment with colesevelam added to anti‐diabetic agents showed significant effects on glycaemic control; however, more research on the reduction of cardiovascular risks is required. Furthermore, long‐term data on the health‐related quality of life and all‐cause mortality also need to be investigated. (Source: Diabetic Medicine)
Source: Diabetic Medicine - September 11, 2013 Category: Endocrinology Authors: C. P. Ooi, S. C. Loke Tags: Systematic Review or Meta‐analysis Source Type: research
The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil.
Abstract
Bile acid sequestrants can potentially bind to concomitant drugs. Single-dose studies evaluated the effects of colesevelam on the pharmacokinetics of glimepiride, glipizide extended-release (ER), and olmesartan medoxomil. Each study enrolled healthy subjects aged 18-45 years. The olmesartan medoxomil study used a randomized adaptive crossover design that initially compared olmesartan medoxomil alone versus simultaneously with colesevelam, then olmesartan medoxomil alone versus 4 hours before colesevelam. The other studies used a three-period crossover design (test drug alone, test drug simultaneou...
Source: The Journal of Clinical Pharmacology - September 10, 2013 Category: Drugs & Pharmacology Authors: He L, Wickremasingha P, Lee J, Tao B, Mendell-Harary J, Walker J, Wight D Tags: J Clin Pharmacol Source Type: research
The Efficacy of Colesevelam HCl in the Treatment of Heterozygous Familial Hypercholesterolemia in Pediatric and Adult Patients.
CONCLUSIONS: Currently available data demonstrate that colesevelam, alone or in combination therapy, is efficacious and well tolerated in the treatment of heterozygous FH in adults and pediatric patients, supporting its use as a treatment option in both of these patient populations.
PMID: 23916045 [PubMed - as supplied by publisher] (Source: Clinical Therapeutics)
Source: Clinical Therapeutics - July 31, 2013 Category: Drugs & Pharmacology Authors: Davidson M Tags: Clin Ther Source Type: research
Real-world utilization patterns and outcomes of colesevelam hcl in the ge electronic medical record
Conclusions:
The 0.44% to 0.47% A1C reduction observed in this study was similar to the reduction observed in RCTs, supporting the real-world effectiveness of colesevelam HCL in reducing A1C. (Source: BMC Endocrine Disorders)
Source: BMC Endocrine Disorders - July 17, 2013 Category: Endocrinology Authors: Richard HansenJoel FarleyMatthew MaciejewskiXin YeChunlin QianBen Powers Source Type: research
Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose
Conclusions: Colesevelam as an adjunct to niacin therapy further lowers LDL-C while obviating the adverse effects of niacin on glucose metabolism in patients with dyslipidemia and IFG. (Source: Journal of Clinical Lipidology)
Source: Journal of Clinical Lipidology - June 13, 2013 Category: Lipidology Authors: Michael H. Davidson, Michael Rooney, Elisabeth Pollock, Joan Drucker, Young Choy Tags: Original Articles Source Type: research
Abstract 277: Colesevelam Hcl Or Ezetimibe For Hypercholesterolemia: Differences In Patient Characteristics From A Healthcare Database [Poster Session III]
CONCLUSIONS: Compared to ezetimibe, colesevelam HCl was administered to a greater percent of patients with type 2 diabetes mellitus and women, which may be related to colesevelam HCl’s approved use as an anti-diabetes mellitus drug, and its pregnancy category B status. The baseline statin use was less common among colesevelam HCI patients than ezetimibe patients. These differences should be taken into account when evaluating real-world effectiveness of the two therapies. (Source: Circulation: Cardiovascular Quality and Outcomes)
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Ye, X., Bays, H., Swindle, J. Tags: Poster Session III Source Type: research
Abstract 275: Concomitant Statin Use With Ezetimibe Or Colesevelam For Treatment Of Hypercholesterolemia [Poster Session III]
CONCLUSIONS: In this claims data analysis, statins were administered along with ezetimibe more frequently than administered with colesevelam, which should be taken into account when evaluating effectiveness of ezetimibe vs. colesevelam in the real-world treatment of hypercholesterolemia. (Source: Circulation: Cardiovascular Quality and Outcomes)
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Ye, X., Bays, H., Schwab, P. Tags: Poster Session III Source Type: research
Bile acid sequestration normalizes plasma cholesterol and reduces atherosclerosis in hypercholesterolemic mice. No additional effect of physical activity
Abstract: Aims: Bile acid sequestrants (BAS) and physical activity (RUN) decrease incidence of cardiovascular events. Both treatments are often prescribed, yet it is not known whether their beneficial effects are additive. We assessed the effects of BAS treatment alone and in combination with RUN on cholesterol metabolism, heart function and atherosclerotic lesion size in hypercholesterolemic mice.Methods: Male Ldlr-deficient mice remained either sedentary (CONTROL), were treated with Colesevelam HCl (BAS), had access to a running wheel (RUN), or were exposed to BAS and RUN (BAS RUN). All groups were fed a high cholesterol...
Source: Atherosclerosis - March 15, 2013 Category: Cardiology Authors: Maxi Meissner, Henk Wolters, Rudolf A. de Boer, Rick Havinga, Renze Boverhof, Vincent W. Bloks, Folkert Kuipers, Albert K. Groen Tags: Metabolism: Lipids, Lipoprotein, Carbohydrates, Homocysteine, Cholesterol Source Type: research
Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice
Bile acid sequestrants are nonabsorbable resins designed to treat hypercholesterolemia by preventing ileal uptake of bile acids, thus increasing catabolism of cholesterol into bile acids. However, sequestrants also improve hyperglycemia and hyperinsulinemia through less characterized metabolic and molecular mechanisms. Here, we demonstrate that the bile acid sequestrant, colesevelam, significantly reduced hepatic glucose production by suppressing hepatic glycogenolysis in diet-induced obese mice and that this was partially mediated by activation of the G protein-coupled bile acid receptor TGR5 and glucagon-like peptide-1 (...
Source: AJP: Gastrointestinal and Liver Physiology - February 15, 2013 Category: Gastroenterology Authors: Potthoff, M. J., Potts, A., He, T., Duarte, J. A. G., Taussig, R., Mangelsdorf, D. J., Kliewer, S. A., Burgess, S. C. Tags: LIVER AND BILIARY TRACT Source Type: research
